Literature DB >> 31806908

Reply to: 'IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma'.

Noam Auslander1, Joo Sang Lee2,3, Eytan Ruppin4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31806908     DOI: 10.1038/s41591-019-0646-5

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.

Authors:  Jenny H Lee; Elena Shklovskaya; Su Yin Lim; Matteo S Carlino; Alexander M Menzies; Ashleigh Stewart; Bernadette Pedersen; Malama Irvine; Sara Alavi; Jean Y H Yang; Dario Strbenac; Robyn P M Saw; John F Thompson; James S Wilmott; Richard A Scolyer; Georgina V Long; Richard F Kefford; Helen Rizos
Journal:  Nat Commun       Date:  2020-04-20       Impact factor: 14.919

2.  Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.

Authors:  Kuang Du; Shiyou Wei; Zhi Wei; Dennie T Frederick; Benchun Miao; Tabea Moll; Tian Tian; Eric Sugarman; Dmitry I Gabrilovich; Ryan J Sullivan; Lunxu Liu; Keith T Flaherty; Genevieve M Boland; Meenhard Herlyn; Gao Zhang
Journal:  Nat Commun       Date:  2021-10-15       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.